Pharmafile Logo
Pharmafocus logo
Advanced Search

Celgene

Showing 15 posts of 128 posts found.

celgene_building

Celgene drops $710m drug, shares nosedive 7%

October 20, 2017
Medical Communications, Research and Development Celgene, biotech, drugs, pharma, pharmaceutical

Celgene took a gamble when it spent $710 million up-front on an inflammatory disorder treatment, but it now looks likely …

News
celgene_1_02

Celgene opts not to acquire Sutro Biopharma for $1bn, reworks existing partnership

August 11, 2017
Medical Communications, Sales and Marketing Celgene, Sutro Biopharma, biotech, healthcare, life sciences, medicine, pharma, pharmaceutical

Celgene has announced that it has chosen not to scoop up Sutro Biopharma, rejecting to take advantage of an option …

News
celgene_1_02

NICE greenlights Celgene pancreatic cancer drug as first-line combination treatment

August 4, 2017
Medical Communications, Sales and Marketing Cancer, Celgene, NICE, Pancreatic cancer, drugs, healthcare, life sciences, medicine, pharma, pharmaceuticals

Celgene is celebrating following NICE’s announcement that it had decided to recommend the use of nab-Paclitaxel, when used in combination …

News
celgene_1_02

FDA approves Celgene and Agios’ acute myeloid leukaemia drug

August 2, 2017
Research and Development, Sales and Marketing Celgene, FDA, Idhifa, acute myeloid leukaemia, agios, biotech, drugs, life sciences, medicines, pharma, pharmaceuticals

The FDA has given its approval for the commercialisation of Celgene and Agios Pharmaceutical’s Idhifa for the treatment of relapsed …

News

Celgene agrees one of the largest settlements for false claims on record

July 26, 2017
Research and Development, Sales and Marketing Celgene, Revlimid, biotech, drugs, pharma, pharmaceutical, thalomid

It has been announced that Celgene has agreed to settle a case after a whistle-blower launched a lawsuit against the …

News
celgene_1_02

Celgene plays catch up with $1.4 billion immunotherapy deal

July 7, 2017
Medical Communications, Sales and Marketing BeiGene, Celgene, immunotherapy, pd-1

Those commentating on Celgene’s latest deal seem to be equally divided between two camps: it is too much money, too …

News
shutterstock_138095450

New data shows pharma has not cut back on controversial payments to physicians

July 6, 2017
Medical Communications, Sales and Marketing Allergan, Biogen, Celgene, Sanofi, Valeant

Despite increasing controversy arising over the years due to the questionable relationship between physicians and pharma and the money which …

News
scott_smith_252

New COO for Celgene

March 1, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene

Celgene released in a statement that its Chief Operating Officer and President, Jacqualyn “Jackie” Fouse, will retire from her position. …

Appointment
celgene_1_02

Celgene announces shock departure of COO

February 27, 2017
Medical Communications, Sales and Marketing Celgene

Celgene released in a statement that its Chief Operating Officer and President, Jacqualyn “Jackie” Fouse, will retire from her position. …

News
celgene_1_02

Celgene’s potential blockbuster gets positive Phase 3 results in multiple sclerosis

February 20, 2017
Research and Development, Sales and Marketing Celgene, multiple sclerosis

Celgene’s drug to treat patients suffering with relapsing multiple sclerosis (RMS) was given a boost by positive Phase 3 trial …

News
donald_trump_september_3_2015

Trump meets with top pharma execs, reiterates pledge to lower “astronomical” prices

January 31, 2017
Manufacturing and Production, Research and Development, Sales and Marketing Celgene, Eli Lilly, Novartis, PhRMA, Trump

President Trump convened with a number of top pharma execs at the White House on Tuesday to discuss the key …

News
revlimid_celgene

Celgene’s Revlimid scores first-of-its-kind myeloma indication in EU

January 27, 2017
Sales and Marketing Celgene, Revlimid, multiple myeloma

Celgene’s Revlimid (lenalidomide) has become the first licensed monotherapy treatment for newly diagnosed multiple myeloma in patients who have undergone …

News
celgene_1_02

Celgene to acquire Delinia in a potential $775 million deal

January 27, 2017
Medical Communications Celgene, Delinia

Celgene has shelled out $300 million upfront, with a potential further $475 million in milestone payments, for Delinia, an autoimmune …

News
access_accelerated

22 pharma companies join forces for global non-communicable disease initiative

January 18, 2017
Research and Development BMS, Celgene, Eisai, Eli Lilly, GSK, J&J, JJ, MSD, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda

The World Economic Forum Annual Meeting in Switzerland has seen the launch of Access Accelerated, a global initiative consisting of …

News
celgene_1_02

NICE u-turns on Celgene’s drug for multiple myeloma

November 24, 2016
Medical Communications Celgene, NICE, imnovid

NICE has performed a U-turn on Celgene’s Imnovid (pomalidomide) based on new data and the offer of a price reduction. …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023